​

Funding Round

Series B - Affinia Therapeutics

Series B - Affinia Therapeutics

Investment Firm

Overview

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.

Announced Date

May 03, 2021

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Farallon Capital Management

Farallon Capital Management

Farallon Capital Management is a early_stage_venture and late_stage_venture and private_equity firm.

EcoR1 Capital

EcoR1 Capital

EcoR1 Capital is a early_stage_venture and late_stage_venture and post_ipo and venture firm.

Participant Investors

15

Investor Name
Participant InvestorF-Prime Capital
Participant InvestorAtlas Venture
Participant InvestorGoogle Ventures
Participant InvestorNew Enterprise Associates
Participant InvestorFarallon Capital Management

Round Details and Background

Affinia Therapeutics raised $110000000 on 2021-05-03 in Series B

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 31, 2020
Series A - Affinia Therapeutics
6-60.0M
May 03, 2021
Series B - Affinia Therapeutics
15-110.0M

Recent Activity

There is no recent news or activity for this profile.